title: S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma.
abstract: OBJECTIVE
  To assess the efficacy and safety of S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma (HCC).
  
  
  METHODS
  PubMed, the Cochrane Library, EMBASE, and ClinicalTrials.gov were searched using the terms "Hepatocellular Carcinoma" or "HCC" or "Hepatoma" or "Liver cancer" and "S-1" and "Sorafenib" or "Nexavar". Outcomes of main interest included overall survival (OS) and toxicities.
  
  
  RESULTS
  We identified 2 studies of S"1 plus sorafenib from 77 references that included a total of 65 patients. The percentage of male patients ranged from 70.0 to 89.5%. Median age was 59.2 years and ranged from 48.0 to 65.5 years. The percentage of hepatitis B virus ranged from 23.1 to 90.0%. The recommended dose of S-1 and sorafenib was 80 or 64 mg/m2/day and 800 mg/day, respectively and treatment was administered orally on days 1-14 and days 1-21, respectively. Median OS were 10.4 and 10.5 months, respectively. The incidence of all-grade toxicities of more than 30% were hand"foot syndrome (HFS) and rash. The incidence of grade 3/4 toxicities more than 5% were thrombocytopenia, elevated AST/ALT and hyperbilirubinemia.
  
  
  CONCLUSIONS
  This systematic review suggests that S-1 plus sorafenib showed modest clinical efficacy and tolerable toxicity profile in patients with advanced HCC. The recommended dose of S-1 and sorafenib was 80 or 64 mg/m2/day and 800 mg/day, respectively.
authors.affiliation: Department of Interventional Radiology, The Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang, People's Republic of China.
authors.forename: Wukui
authors.initials: W
authors.lastname: Huang
authors.forename: Lina
authors.initials: L
authors.lastname: You
authors.forename: Dengyao
authors.initials: D
authors.lastname: Liu
authors.forename: Shufa
authors.initials: S
authors.lastname: Yang
authors.forename: Mo
authors.initials: M
authors.lastname: Liu
authors.forename: Hailin
authors.initials: H
authors.lastname: Wang
authors.forename: Pingju
authors.initials: P
authors.lastname: Wang
authors.forename: Pahaerding
authors.initials: P
authors.lastname: Baikere
authors.forename: Peng
authors.initials: P
authors.lastname: Gu
authors.forename: Abulajiang
authors.initials: A
authors.lastname: Abulikemu
authors.forename: Shaoha
authors.initials: S
authors.lastname: Yuan
authors.forename: Xiwen
authors.initials: X
authors.lastname: Fan
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000077157:Sorafenib; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; C079198:S 1 (combination); D005641:Tegafur; D009536:Niacinamide; D010094:Oxonic Acid; D000077157:Sorafenib